Finoriq research workspace
Avalyn Pharma Inc. (AVLN) SEC Filings & Filing Highlights
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled. Review AVLN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
- Company
- Avalyn Pharma Inc. (AVLN)
- Ticker
- AVLN
- Market Cap
- $1.3B
- Latest Price
- $28.61
- Industry
- Biotech & Pharma
Avalyn Pharma Inc. (AVLN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Avalyn Pharma Inc. (AVLN).
| Event | Form | Date |
|---|---|---|
| Additionally, under the terms of the Sublease Amendment, the Company’s future minimum lease pay...On June 29, 2026 (the “Effective Date”), Avalyn Pharma Inc. (the “Company”) entered into a First Amendment to the Sublease (the “Sublease A... | 8-K1.01 | 2026-07-01 |
| Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 for Patients with Progressive...Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis | 8-K7.01 | 2026-06-17 |
| Avalyn Reports First Quarter 2026 Financial Results and Recent Business HighlightsAvalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights | 8-K2.02 | 2026-06-03 |
| Avalyn Pharma Inc.: Governance or capital structure updateAs previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-294932) (the “Registration Statement”) of Avaly... | 8-K5.03 | 2026-05-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.